Results of combined photodynamic therapy (PDT) and high dose rate brachytherapy (HDR) in treatment of obstructive endobronchial non-small cell lung cancer (NSCLC)

SummaryIntroductionWe reviewed the outcome of combined photodynamic therapy (PDT) and high dose rate brachytherapy (HDR) for patients with symptomatic obstruction from endobronchial non-small cell lung cancer.MethodsNine patients who received combined PDT and HDR for endobronchial cancers were identified and their charts reviewed. The patients were eight males and one female aged 52–73 at diagnosis, initially presenting with various stages of disease: stage IA (N = 1), stage IIA (N = 1), stage III (N = 6), and stage IV (N = 1). Intervention was with HDR (500 cGy to 5 mm once weekly for 3 weeks) and PDT (2 mg/kg Photofrin®, followed by 200 J/cm2 illumination 48 h post-infusion). Treatment group 1 (TG-1, N = 7) received HDR first; Treatment group 2 (TG-2, N = 2) received PDT first. Patients were followed by regular bronchoscopies.ResultsTreatments were well tolerated, all patients completed therapy, and none were lost to follow-up. In TG-1, local tumor control was achieved in six of seven patients for: 3 months (until death), 15 months, 2+ years (until death), 2+ years (ongoing), and 5+ years (ongoing, N = 2). In TG-2, local control was achieved in only one patient, for 84 days. Morbidities included: soft-tissue contraction and/or other reversible benign local tissue reactions (N = 8) and photosensitivity reactions (N = 2).ConclusionsCombined HDR/PDT treatment for endobronchial tumors is well tolerated and can achieve prolonged local control with acceptable morbidity when PDT follows HDR and when the spacing between treatments is 1 month or less. This treatment regimen should be studied in a larger patient population.